GLP-1 medications have rapidly become one of the most significant developments in obesity treatment in decades. Many patients achieve substantial weight loss, often with improvements in blood pressure, lowering of cardiovascular risk factors, and lessened sleep apnea symptoms.
To stay with the times, the Federal Aviation Administration has quietly modernized its approach to weight-loss treatment and medical certification as medications like Wegovy®, Ozempic®, and Zepbound® have become increasingly common among pilots and other aviation professionals.
The FAA’s updated “Weight Loss Management” disposition guidance now provides a clearer certification pathway for many applicants. The distinction between receiving an immediate issuance and facing an FAA deferral may now come down to a few important factors: is the prescribed medication acceptable to the FAA, are you taking a combination of medicines, or just one, and have you ever been diagnosed with diabetes.
The FAA’s Three-Tier Weight-Loss Framework
Under the FAA’s March 2024 Weight Loss Management disposition table, applicants fall into three primary categories based on their treatment method. It is important to note that if you have been diagnosed with diabetes, the FAA will instead evaluate you under its diabetes certification protocols, which carry significantly stricter requirements.
Lifestyle Modification and OTC Treatment
Pilots using diet, exercise, behavioral modification, or approved over-the-counter medications (Orlistat, also known as Alli®) generally face the least scrutiny during the medical certification process.
If your Aviation Medical Examiner (AME) determines your condition is stable, symptoms are controlled, and there are no medication side effects that could impair safe operation of an aircraft, the AME may issue the medical certificate during the exam.
One Prescription Medication
The FAA’s current guidance is particularly important for pilots using a single GLP-1 medication for weight management.
Under the agency’s Conditions AMEs Can Issue (CACI) pathway, pilots taking one qualifying non-insulin diabetic medication component may still receive their medical certificate directly from the AME without FAA deferral.
Common medications in this category include:
- Semaglutide (Wegovy/Ozempic)
- Tirzepatide (Zepbound/Mounjaro®)
- Liraglutide
- Metformin
To qualify for same-day issuance, the FAA requires several conditions be met:
- A current, detailed clinical progress note from your treating physician that meets FAA specifications
- Hemoglobin A1c testing within the previous 90 days
- An A1c below diabetic thresholds (6.4% or lower)
- No significant medication side effects
- No episodes of hypoglycemia requiring assistance
The FAA also requires observation periods before pilots may resume flying duties after starting or adjusting medication dosages. These waiting periods are intended to ensure pilots do not experience side effects that could affect aeromedical performance. Typically, the FAA requires a two-week observation after starting the medication, and a 48-hour observation for dosage changes.
When Certification Becomes More Complicated
The FAA draws a much firmer line once a pilot begins taking two or more diabetic-type medication components simultaneously.
Examples could include:
- Metformin combined with Wegovy
- Zepbound combined with another glucose-management medication
- Multiple GLP-1 agents prescribed together
In these situations, AMEs are generally required to defer the application to the FAA for possible Special Issuance (SI) consideration.
That process may require:
- A detailed clinical progress note
- A Weight Loss Management Status Report
- Documentation explaining the reason for treatment
- Clarification regarding any history of diabetes
Unlike CACI issuance, deferred cases often involve longer review timelines and additional FAA oversight.
Aeromedically Unacceptable Weight Loss Medications
Not all medications that are prescribed for weight loss are acceptable for FAA medical certification. Currently, all FDA approved GLP-1 Agonists (Ozempic, Wegovy, Zepbound, etc.) are acceptable. However, the class of drugs known as “Sympathomimetics” are prohibited. Sympathomimetic drugs are stimulants, prescribed to suppress appetite, and aid in short term weight loss. Common forms of Sympathomimetic drugs are benzphetamine (Regimex®), diethylpropion (Tenuate®, Tempanil®), phendimetrazine (Bontril®), phentermine (Adipex®, Fastin®).
What Pilots Should Do Before Starting Medication
Should you decide to pursue weight loss through medication, keep the following in mind:
- Only certain medications are acceptable for FAA medical certification
- Understand observation requirements
- Keep documentation organized
- Monitor side effects carefully
Airman should consult with their AME before beginning any prescription weight-loss medication and possibly speak with an aviation attorney.
If you need assistance protecting your FAA medical certificate, you may want to reach out to Ramos Law to request a consultation with an aviation attorney.
